p12CDK2-AP1 gene therapy strategy inhibits tumor growth in an in vivo mouse model of head and neck cancer

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3939-3948

  Figueiredo, Marxa L ^a   Kim, Yong ^a   St John, Maie A R ^a   Wong, David T W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; LIPOSOME; P12 CDK2 AP1; UNCLASSIFIED DRUG; CDK2AP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; GENE TARGETING; HEAD AND NECK CANCER; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; ANIMAL; ANIMAL DISEASE; DISEASE COURSE; DISEASE MODEL; GENE THERAPY; GENETICS; HEAD AND NECK TUMOR; PATHOLOGY; XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE THERAPY; HEAD AND NECK NEOPLASMS; MICE; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

EID: 18844365357     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2085     Document Type: Article

References (53)

1. American Cancer Society. Cancer facts and figures 2004. Atlanta, GA: American Cancer Society; 2004.
2. O'Malley BW Jr, Couch ME. Gene therapy principles and strategies for head and neck cancer. Adv Otorhinolaryngol 2000;56:279-88.
3. Barzon L, Boscaro M, Palu G. Endocrine aspects of cancer gene therapy. Endocr Rev 2004;25:1-44.
4. Nemunaitis J, O'Brien J. Head and neck cancer: gene therapy approaches. Part II: genes delivered. Expert Opin Biol Ther 2002;2:311-24.
5. Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 1998;4:835-46.
6. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome- mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999;10:2941-52.
7. Mobley SR, Liu TJ, Hudson JM, Clayman GL. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck: a research model for combination gene therapy. Arch Otolaryngol Head Neck Surg 1998;124:88-92.
8. Rocco JW, Li D, Liggett WH, et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 1998;4:1697-704.
9. Li D, Day KV, Yu S, et al. The role of adenovirus-mediated retinoblastoma 94 in the treatment of head and neck cancer. Cancer Res 2002;62:4637-44.
10. Le QT, Giaccia AJ. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res 2003;9:4287-95.
11. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
12. Shintani S, Mihara M, Terakado N, et al. Reduction of p12DOC-1 expression is a negative prognostic indicator in patients with surgically resected oral squamous cell carcinoma. Clin Cancer Res 2001;7:2776-82.
13. Shintani S, Mihara M, Nakahara Y, et al. Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol 2002;38:235-43.
14. Tsuji T, Duh FM, Latif F, et al. Cloning, mapping, expression, function, and mutation analyses of the human ortholog of the hamster putative tumor suppressor gene Doc-1. J Biol Chem 1998;273:6704-9.
15. Shintani S, Ohyama H, Zhang X, et al. p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein. Mol Cell Biol 2000;20:6300-7.
16. Matsuo K, Shintani S, Tsuji T, et al. p12(DOC-1), a growth suppressor, associates with DNA polymerase α/primase. FASEB J 2000;14:1318-24.
17. Todd R, McBride J, Tsuji T, et al. Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB J 1995;9:1362-70.
18. Cwikla SJ, Tsuji T, McBride J, Wong DT, Todd R. doc-1-mediated apoptosis in malignant hamster oral keratinocytes. J Oral Maxillofac Surg 2000;58:406-14.
19. Kohno Y, Patel V, Kim Y, et al. Apoptosis, proliferation and p12(doc-1) profiles in normal, dysplastic and malignant squamous epithelium of the Syrian hamster cheek pouch model. Oral Oncol 2002;38:274-80.
20. Kim Y, McBride J, Zhang R, Zhou X, Wong DT. p12(CDK2-AP1) mediates DNA damage responses induced by cisplatin. Oncogene 2005;24:407-18.
21. Rhee JG, Li D, O'Malley BW Jr, Suntharalingam M. Combination radiation and adenovirus-mediated P16(INK4A) gene therapy in a murine model for head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2003;65:144-54.
22. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997;15:647-52.
23. Iyer M, Berenji M, Templeton NS, Gambhir SS. Non-invasive imaging of cationic lipid-mediated delivery of optical and PET reporter genes in living mice. Mol Ther 2002;6:555-62.
24. Ramesh R, Saeki T, Templeton NS, et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 2001;3:337-50.
25. O'Malley BW Jr, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-4.
26. Li D, Jiang W, Bishop JS, Ralston R, O'Malley BW Jr. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Clin Cancer Res 1999;5:1551-6.
27. Bray D, Yu SZ, Koprowski H II, et al. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2003;129:618-22.
28. Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL Jr. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res 2004;10:3528-34.
29. Semba T, Funahashi Y, Ono N, et al. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin α2 on platelets as a biological marker. Clin Cancer Res 2004;10:1430-8.
30. Soini Y, Paakko P, Lehto VP. Histopathological evaluation of apoptosis in cancer. Am J Pathol 1998;153:1041-53.
31. Kappler M, Kotzsch M, Bartel F, et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 2003;9:1098-104.
32. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
33. Fu KK, Rayner PA, Lam KN. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys 1984;10:1473-8.
34. Ito I, Ji L, Tanaka F, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004;11:733-9.
35. Li D, Ronson B, Guo M, et al. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. Cancer Res 2002;62:4023-8.
36. Silva SD, Agostini M, Nishimoto IN, et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. Oral Oncol 2004;40:688-96.
37. Jacob R, Welkoborsky HJ, Mann WJ, Jauch M, Amedee R. [Fluorine-18] fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. ORL J Otorhinolaryngol Relat Spec 2001;63:307-13.
38. Yuan Z, Sotsky Kent T, Weber TK. Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer. Oncogene 2003;22:6304-10.
39. Sotsky Kent T, Yuan Z, Miller A, Weber TK. Deleted in oral cancer-1 expression upregulates proapoptosis elements in microsatellite-unstable human colorectal cancer. Ann Surg Oncol 2004;11:192-6.
40. Buajeeb W, Zhang X, Ohyama H, et al. Interaction of the CDK2-associated protein-1, p12(DOC-1/CDK2AP1), with its homolog, p14(DOC-1R). Biochem Biophys Res Commun 2004;315:998-1003.
41. Li D, Shugert E, Guo M, Bishop JS, O'Malley BW Jr. Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:1319-24.
42. Day KV, Li D, Liu S, Guo M, O'Malley BW Jr. Granulocyte-macrophage colony-stimulating factor in a combination gene therapy strategy for head and neck cancer. Laryngoscope 2001;111:801-6.
43. Li M, Ye C, Feng C, et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002;8:3570-8.
44. Overholt SM, Liu TJ, Taylor DL, et al. Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker for gene therapy trials. Clin Cancer Res 1997;3:185-91.
45. Pirollo KF, Hao Z, Rait A, et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997;14:1735-46.
46. Clayman GL, Liu TJ, Overholt SM, et al. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch Otolaryngol Head Neck Surg 1996;122:489-93.
47. Akimoto T, Seong J, Hunter NR, Buchmiller L, Mason K, Milas L. Association of increased radiocurability of murine carcinomas with low constitutive expression of p21 (WAF1/CIP1) protein. Int J Radiat Oncol Biol Phys 1999;44:413-9.
48. Milas L, Akimoto T, Hunter NR, et al. Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 2002;52:514-21.
49. Yang YS, Guccione S, Bednarski MD. Comparing genomic and histologic correlations to radiographic changes in tumors: a murine SCC VII model study. Acad Radiol 2003;10:1165-75.
50. Saito Y, Milross CG, Hittelman WN, et al. Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction. Int J Radiat Oncol Biol Phys 1997;38:623-31.
51. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-90.
52. Villaret D, Glisson B, Kenady D, et al. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002;24:661-9.
53. Yoo GH, Hung MC, Lopez-Berestein G, et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001;7:1237-45.